Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design

Area of Science:

• Immunotherapy
• Cell Biology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy requires optimized ex vivo cell culture for T cell activation, expansion, and CAR gene delivery.
• Current media formulations often use serum (FBS or HS), which have limitations in consistency and supply, and lack optimization for CAR-T cell manufacturing.
• Bioactive components crucial for generating potent, persistent T cell progeny are not well-defined in existing media.

Purpose of the Study:

• To investigate the efficacy of a xeno-free human growth factor concentrate (Phx) in supporting CAR-T cell expansion and function.
• To evaluate Phx as a potential alternative to serum-based media in CAR-T cell manufacturing.
• To explore the impact of Phx on lentiviral gene delivery and in vivo therapeutic potency.

Main Methods:

• CAR-T cells were cultured ex vivo in media supplemented with Phx or human serum (HS).
• Lentiviral gene delivery efficiency and T cell proliferation were assessed.
• In vitro cytolytic activity and in vivo tumor clearance in a human xenograft neuroblastoma model were evaluated.
• Metabolomic profiling was performed to identify key components in Phx.

Main Results:

• Phx supported T cell proliferation in various media formulations.
• Phx enhanced lentiviral-mediated gene expression across a range of multiplicities of infection (MOIs).
• CAR-T cells expanded in Phx demonstrated superior in vivo engraftment, potency, and in vitro CAR-induced cytolytic activity compared to those expanded in HS.
• Metabolomic analysis identified carnosine in Phx as a factor enhancing lentiviral gene delivery and improving T cell metabolic fitness.

Conclusions:

• Phx is a promising xeno-free supplement for CAR-T cell manufacturing, improving T cell expansion, gene delivery, and in vivo potency.
• The unique composition of Phx, including carnosine, contributes to enhanced T cell function and metabolic health.
• These findings support the development of customized media for T cell adoptive immunotherapies, optimizing gene delivery and overall therapeutic efficacy.